市場調査レポート

脊髄性筋萎縮症市場:パイプライン分析・市場規模の実績&予測・成長率・市場動向 (2015-2023年)

Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023

発行 Transparency Market Research 商品コード 345767
出版日 ページ情報 英文 44 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
脊髄性筋萎縮症市場:パイプライン分析・市場規模の実績&予測・成長率・市場動向 (2015-2023年) Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023
出版日: 2015年10月16日 ページ情報: 英文 44 Pages
概要

当レポートでは、脊髄性筋萎縮症治療薬の市場について調査し、脊髄性筋萎縮症の概要と現在の治療法、市場成長への各種影響因子の分析、パイプラインの動向、提言、主要事業者のプロファイルなどをまとめています。

第1章 イントロダクション

  • レポート概要
  • 調査手法
  • 市場区分
  • 前提因子

第2章 エグゼクティブサマリー

  • 市場概要

第3章 市場概要

  • 市場の定義・概要
  • 脊髄性筋萎縮症:現在の治療法
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 制約
    • 市場機会
  • 市場の魅力度分析

第4章 パイプライン分析

  • 脊髄性筋萎縮症:パイプラインの概要
  • 開発後期の候補薬 (第3相)
    • ISIS-SMN Rx
  • 開発初期の候補薬 (第1・2相)
    • Olesoxime (TRO19622)
    • LMI070
    • RO6885247
    • CK-2127107
    • scAAV9.CB.SMN
    • RG3039

第5章 提言

第6章 企業プロファイル

  • AveXis, Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Isis Pharmaceuticals, Inc.
目次

Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness analysis considers various factors such as patient population, drug pricing policies, regulatory restrictions, current competition intensity, and current state of healthcare sector for assessing the potential of each geographical market.

In the pipeline analysis of spinal muscular atrophy (SMA) market report, market analysis and forecast has been provided for late stage (phase 3) candidates, while also includes thorough qualitative information for other candidates in early stage (phase 1 and phase 2). ISIS-SMNRx by Isis Pharmaceuticals is presently the only late stage candidate in spinal muscular atrophy pipeline, while three drugs are currently in phase 2 and three others in phase 1. These include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039. The report also mentions some of the potential preclinical candidates in the spinal muscular atrophy pipeline. The pipeline analysis of spinal muscular atrophy (SMA) market report provides overview of the clinical trials, and its current status for each drug candidate for treatment of spinal muscular atrophy. Details on mergers, acquisitions, licensing agreements, and other collaborative agreements, updated on regulatory policies, and expected study completion are also mentioned in the report. Market estimation and forecast for phase 3 drugs for treatment of spinal muscular atrophy has been provided from the expected year of drug approval, till 2023 (in USD Million) for the United States.

Pipeline analysis of late stage (phase 3) drugs for treatment of spinal muscular atrophy adopts patient based approach, in which actual patient population that can be targeted by the new drug is considered to arrive at probable sales of the drug in the launch year. Forecast model considers various macro- as well as micro-economic factors such as drug efficiency, side effects, prevalence and incidence rate, impact of regulatory policies, impact of competitor drugs and generic competition (if applicable) and pipeline status. The report collates information from various government as well as corporate sources such as Europe and the U.S. clinical trial registries, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), CureSMA, Families of SMA, PubMed, company press releases, annual reports and investor presentations. The analysis also considers inputs from industry experts and key opinion leaders with expertise in rare disease drug discovery, and marketing and sales experts.

Key players with potential candidates in clinical trials for treatment of spinal muscular atrophy have been profiled in the report. These include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation
  • 1.4 Assumptions

Chapter 2 Executive Summary

  • 2.1 Pipeline Analysis: Spinal Muscular Atrophy- Market Snapshot

Chapter 3 Pipeline Analysis: Spinal Muscular Atrophy Market Overview

  • 3.1 Market Definition and Overview
  • 3.2 Current Treatment for Spinal Muscular Atrophy
  • 3.3 Market Dynamics
    • 3.3.1 Drivers
    • 3.3.2 Restraints
    • 3.3.3 Opportunities
  • 3.3 Market Attractiveness Analysis

Chapter 4 : Pipeline Analysis: Spinal Muscular Atrophy

  • 4.1 Spinal Muscular Atrophy: Pipeline Overview
  • 4.2 Late Stage Candidates (Phase 3)
    • 4.2.1 ISIS-SMN Rx
  • 4.3 Early Stage Candidates (Phase 1 and Phase 2)
    • 4.3.1 Olesoxime (TRO19622)
    • 4.3.2 LMI070
    • 4.3.3 RO6885247
    • 4.3.4 CK-2127107
    • 4.3.5 scAAV9.CB.SMN
    • 4.3.6 RG3039

Chapter 5 Recommendation

Chapter 6 Company Profiles

  • 6.1 AveXis, Inc.
  • 6.2 Cytokinetics, Inc.
  • 6.3 F. Hoffmann-La Roche Ltd.
  • 6.4 Novartis AG
  • 6.5 Isis Pharmaceuticals, Inc.
Back to Top